Apretude vs Descovy
A side-by-side look at two hiv medications advertised on TV. Informational only — not medical advice.
| US Apretude | US Descovy | |
|---|---|---|
| Generic name | cabotegravir | emtricitabine/tenofovir alafenamide |
| Drug class | Integrase Inhibitor (Long-Acting Injectable PrEP) | NRTI Combination |
| Treats | HIV prevention (PrEP) | HIV treatment and prevention (PrEP) |
| Category | HIV | HIV |
| Manufacturer | ViiV Healthcare | Gilead Sciences |
| Year approved | 2021 | 2016 |
| FDA warning | Moderate warnings | Black box warning |
| Est. TV ad spend | — | — |
| Common side effects | Injection site reactions, Headache, Fever, Fatigue | Diarrhea, Nausea, Headache, Worsening of hepatitis B if stopped (boxed warning) |
Frequently asked questions
Is Apretude or Descovy better?
Neither is universally "better." Apretude (cabotegravir) and Descovy (emtricitabine/tenofovir alafenamide) are both used for hiv, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Apretude and Descovy?
Apretude is a Integrase Inhibitor (Long-Acting Injectable PrEP) made by ViiV Healthcare, while Descovy is a NRTI Combination made by Gilead Sciences. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Apretude has the larger estimated TV advertising budget of the two.